Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameBiostar Pharm-B
Stock Code02563
Company Full NameBeijing Biostar Pharmaceuticals Co., Ltd.
Industry醫療保健
Principal Activities公司是由留美科學家團隊創立的國家級高新技術企業,依托先進且可持續的合成生物學新藥研發平臺,專注于開發具有自主知識產權的抗癌新藥,經過20余年的發展,公司已成為集新藥研發、生產和商業化為一體的整合型生物醫藥公司。
Listing Date2024-10-31
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市北京經濟技術開發區亦城財富中心B座1202室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.biostar-pharm.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 16.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 3,200
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares14,588,000 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share76.2%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 233,408,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 3,200
2 lots 400 HK$ 6,400
3 lots 600 HK$ 9,600
4 lots 800 HK$ 12,800
5 lots 1,000 HK$ 16,000
6 lots 1,200 HK$ 19,200
7 lots 1,400 HK$ 22,400
8 lots 1,600 HK$ 25,600
9 lots 1,800 HK$ 28,800
10 lots 2,000 HK$ 32,000
15 lots 3,000 HK$ 48,000
20 lots 4,000 HK$ 64,000
25 lots 5,000 HK$ 80,000
30 lots 6,000 HK$ 96,000
35 lots 7,000 HK$ 112,000
40 lots 8,000 HK$ 128,000
45 lots 9,000 HK$ 144,000
50 lots 10,000 HK$ 160,000
100 lots 20,000 HK$ 320,000
150 lots 30,000 HK$ 480,000
200 lots 40,000 HK$ 640,000
250 lots 50,000 HK$ 800,000
300 lots 60,000 HK$ 960,000
350 lots 70,000 HK$ 1,120,000
400 lots 80,000 HK$ 1,280,000
450 lots 90,000 HK$ 1,440,000
500 lots 100,000 HK$ 1,600,000
750 lots 150,000 HK$ 2,400,000
1,000 lots 200,000 HK$ 3,200,000
1,250 lots 250,000 HK$ 4,000,000
1,500 lots 300,000 HK$ 4,800,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 400,000 HK$ 6,400,000
2,250 lots 450,000 HK$ 7,200,000
2,500 lots 500,000 HK$ 8,000,000
2,750 lots 550,000 HK$ 8,800,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.45B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +549%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 38.09 million
Listing ExpensesTo be extracted
Listing Expenses / Funds Raised~15.6%
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 20.8
First Day OpenHK$ 21.5
First Day Change30.00%
First Day Volume3185800.0
First Day Turnover69538800.0
Use of Proceeds
1、約44.9%或105.1百萬港元,將用于資助核心產品的進行中及計劃進行的臨床試驗; 2、約38.9%或91.1百萬港元,將用于資助核心產品以外的進行中及計劃進行的臨床試驗及產品臨床前研究以及核心產品研究者發起的試驗; 3、約3.0%或7.0百萬港元,將用于加強公司的國內商業化能力及建立公司的全球營銷網絡; 4、約3.2%或7.4百萬港元,將用于擴大產能; 5、約10.0%或23.4百萬港元,將用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
建银国际金融有限公司 CE AJO225 中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (2)
建银国际金融有限公司 CE AJO225 中信建投(国际)融资有限公司 CE BAU112
Joint Bookrunners (16)
建银国际金融有限公司 CE AJO225 中信建投(国际)融资有限公司 CE BAU112 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 民银证券有限公司 CE APU820 SPDB International Capital Limited CE BFZ375 中国银河国际证券(香港)有限公司 CE AXM459 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 Fosun International Securities Limited CE AAF432 GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594 SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330 FIRST SHANGHAI SECURITIES LIMITED CE ABV488 PATRONS SECURITIES LIMITED CE BPQ161 MOUETTE SECURITIES COMPANY LIMITED CE BLE877 CITRUS SECURITIES LIMITED CE BPX754
Joint Lead Managers (17)
建银国际金融有限公司 CE AJO225 中信建投(国际)融资有限公司 CE BAU112 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 民银证券有限公司 CE APU820 SPDB International Capital Limited CE BFZ375 中国银河国际证券(香港)有限公司 CE AXM459 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 ORIENT SECURITIES (HONG KONG) LIMITED CE AVD362 Fosun International Securities Limited CE AAF432 GUOYUAN SECURITIES BROKERAGE (HONG KONG) LIMITED CE AOA594 SHANXI SECURITIES INTERNATIONAL LIMITED CE BEM330 FIRST SHANGHAI SECURITIES LIMITED CE ABV488 PATRONS SECURITIES LIMITED CE BPQ161 MOUETTE SECURITIES COMPANY LIMITED CE BLE877 CITRUS SECURITIES LIMITED CE BPX754 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Novotech SG Holdings Pte. Ltd. 23,081,600 HKD — 9.89% — 6 months 2025-04-30
2 Silky Water Absolute Return LPF 61,555,200 HKD — 26.37% — 6 months 2025-04-30
3 百洋健康产业国际商贸有限公司 15,376,000 HKD — 6.59% — 6 months 2025-04-30
4 富策控股有限公司 77,721,600 HKD — 33.30% — 6 months 2025-04-30

Directors & Management

PositionChinese nameEnglish Name
Chairman唐莉—
Company Secretary劉開林,陳奕斌—
No director data available.

Major Shareholders

Major Shareholders & HoldingsBaygen QT Inc.(11.11%),珠海京蓉昊緣投資合伙企業(有限合伙)(5.59%),珠海華錦昊緣企業管理合伙企業(有限合伙)(5.27%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO saw a moderate oversubscription of 21.45 times, reflecting steady but not frenzied demand. The overall hit rate of 27.47% is relatively high, indicating ample allocation for most applicants. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

A-tail applicants applying HKD 200,000 were allocated an expected 0.4444 lots, nearly identical to B-head applicants with HKD 250,000 who received 0.4615 lots, making the marginal benefit of the higher tier negligible. Given the clawback reallocation, this inefficiency suggests B-head may incur higher broker fees for minimal extra allocation. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

The demographic breakdown shows zero participants recorded for both mainland and Hong Kong categories, likely due to data limitations, so no regional or demographic trends can be inferred. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Biostar Pharm-B (02563) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect